Newland Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Revenue	649.97	662.81	720.99	643.85	621.21	508.93
Other Revenue	9.57	9.57	5.44	7.59	6.15	4.91
Revenue	659.54	672.38	726.44	651.44	627.36	513.84
Revenue Growth (YoY)	-13.41%	-7.44%	11.51%	3.84%	22.09%	18.63%
Cost of Revenue	455.75	447.24	437.43	392.84	404.01	307.82
Gross Profit	203.79	225.14	289	258.6	223.36	206.02
Selling, General & Admin	59.22	55.91	47.62	44.49	38.83	31.56
Research & Development	40.17	46.18	55.49	51.96	30	20.59
Other Operating Expenses	7.45	4.43	2.71	3.89	6.99	6.4
Operating Expenses	105.65	105.66	108.1	96.75	78.04	69.69
Operating Income	98.14	119.49	180.91	161.85	145.31	136.33
Interest Expense	-0.11	-0.21	-0.09	-0.13	-6.88	-6.71
Interest & Investment Income	8.83	10.94	16.7	19.63	1.34	0.26
Currency Exchange Gain (Loss)	-0.03	-0.03	0.25	0.06	0.29	-0.13
Other Non Operating Income (Expenses)	0.19	-0.02	-0.06	-0.12	-0.09	-0.06
EBT Excluding Unusual Items	107.01	130.16	197.7	181.29	139.97	129.69
Gain (Loss) on Sale of Investments	1.42	0.19	-0.23	0.04	1.36	0.17
Gain (Loss) on Sale of Assets	0.33	-	-	0.07	-0.44	-0.21
Asset Writedown	-4.18	-1.49	-2.62	-1.46	-0.32	-0.11
Other Unusual Items	6.51	5.26	2.5	1.22	2.31	2.4
Pretax Income	111.08	134.12	197.35	181.16	142.88	131.94
Income Tax Expense	11.76	14.06	24.34	23.96	11.17	17.11
Earnings From Continuing Operations	99.32	120.07	173.01	157.2	131.71	114.82
Minority Interest in Earnings	1.45	1.18	0.62	1.78	0.6	0.15
Net Income	100.78	121.25	173.63	158.98	132.3	114.98
Net Income to Common	100.78	121.25	173.63	158.98	132.3	114.98
Net Income Growth	-42.18%	-30.17%	9.21%	20.16%	15.07%	-2.94%
Shares Outstanding (Basic)	391	391	395	391	302	294
Shares Outstanding (Diluted)	391	391	395	391	302	294
Shares Change (YoY)	-0.94%	-0.88%	1.05%	29.52%	2.59%	0.64%
EPS (Basic)	0.26	0.31	0.44	0.41	0.44	0.39
EPS (Diluted)	0.26	0.31	0.44	0.41	0.44	0.39
EPS Growth	-41.63%	-29.54%	8.08%	-7.22%	12.17%	-3.36%
Free Cash Flow	-2.85	15.55	15.97	162.94	8.5	23.68
Free Cash Flow Per Share	-0.01	0.04	0.04	0.42	0.03	0.08
Dividend Per Share	0.200	0.200	0.400	0.204	0.170	-
Dividend Growth	-50.00%	-50.00%	95.98%	19.99%	-	-
Gross Margin	30.90%	33.48%	39.78%	39.70%	35.60%	40.09%
Operating Margin	14.88%	17.77%	24.90%	24.85%	23.16%	26.53%
Profit Margin	15.28%	18.03%	23.90%	24.40%	21.09%	22.38%
Free Cash Flow Margin	-0.43%	2.31%	2.20%	25.01%	1.35%	4.61%
EBITDA	155	172.06	216.31	190.69	167.38	157.19
EBITDA Margin	23.50%	25.59%	29.78%	29.27%	26.68%	30.59%
D&A For EBITDA	56.86	52.57	35.4	28.84	22.06	20.86
EBIT	98.14	119.49	180.91	161.85	145.31	136.33
EBIT Margin	14.88%	17.77%	24.90%	24.85%	23.16%	26.53%
Effective Tax Rate	10.59%	10.48%	12.33%	13.23%	7.82%	12.97%
Revenue as Reported	659.54	672.38	726.44	651.44	627.36	513.84
Advertising Expenses	-	1.1	0.85	0.51	0.2	0.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.